Ratings by Guggenheim (Debjit Chattopadhyay)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
6/27/2022 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Buy) |
147.50 (145.83) |
-1.13% | Details | |
5/2/2022 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
4/5/2022 | Taysha Gene Therapies | TSHA | Maintain | Buy (N/A) |
|
Details | ||
3/1/2022 | Ionis Pharmaceuticals | IONS | New Coverage | Buy (N/A) |
33.38 (37.57) |
12.55% | Details | |
3/1/2022 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
2/25/2022 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
2/24/2022 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
2/3/2022 | Alnylam Pharmaceuticals | ALNY | Upgrade | Buy (Neutral) |
145.26 (145.83) |
0.39% | Details | |
1/5/2022 | Beam Therapeutics Inc | BEAM | New Coverage | Buy (N/A) |
78.31 (38.58) |
-50.73% | Details | |
12/16/2021 | Taysha Gene Therapies | TSHA | New Coverage | Buy (N/A) |
14.24 (3.70) |
-74.02% | Details | |
12/1/2021 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
10/5/2021 | Intellia Therapeutics | NTLA | New Coverage | (N/A) |
126.78 (52.39) |
-58.68% | Details | |
7/15/2021 | Ultragenyx Pharma | RARE | New Coverage | Neutral (N/A) |
84.74 (60.00) |
-29.2% | Details | |
5/6/2021 | Freeline | FRLN | New Coverage | Buy (N/A) |
11.25 (0.87) |
-92.27% | Details | |
1/7/2021 | Sangamo BioSciences | SGMO | New Coverage | Neutral (N/A) |
16.01 (4.20) |
-73.77% | Details | |
1/6/2021 | uniQure BV | QURE | Upgrade | Buy (Neutral) |
37.77 (18.52) |
-50.97% | Details |